Econcare, 5 Chatzigianni Mexi Str., 115 28, Athens, Greece.
Econcare, 5 Chatzigianni Mexi Str., 115 28, Athens, Greece.
Hellenic J Cardiol. 2021 May-Jun;62(3):234-240. doi: 10.1016/j.hjc.2020.06.013. Epub 2020 Jul 17.
To estimate the incidence of hemorrhagic events in patients with atrial fibrillation (AF) treated with acenocoumarol, and the management cost of those requiring hospitalization in Greece.
A nationwide telephone survey was conducted between December 2017 and January 2018, to identify cardiologists who treat AF patients with acenocoumarol. A total of 300 cardiologists were selected and reported the number of AF acenocoumarol-treated patients during the past 12 months and the number of those who experienced a hemorrhagic event. The hospital charges to sickness fund and the cost of resource utilization of AF patients hospitalized between January 2013 and June 2017 at a tertiary hospital in Athens due to acenocoumarol-related bleedings were retrieved.
Out of 48,255 AF patients, 12,633 (26.2%) were treated with acenocoumarol. In all, 5.1% of patients experienced a hemorrhagic event with the incidence of bleeding requiring hospitalization being 1.7%. The most common bleeding site was the gastrointestinal system (51.5%). The mean (95% CI) management cost per bleeding event requiring hospitalization was €1,202 (€1,058-€1,420). The higher cost was that of intracranial bleeding €3,887 (€2,700-€5,046). The expected annual economic burden for the management of bleedings related to acenocoumarol and requiring hospitalization was estimated at €1,463,955.
The incidence of bleeding events in AF acenocoumarol-treated patients in Greece as well as the estimated annual economic burden for the management of bleeding events requiring hospitalization, emphasize the need to comply with the current guidelines and to optimize therapeutic strategies for the management of AF side effects with oral anticoagulants, particularly in patients with high bleeding risk.
评估在希腊使用华法林治疗的心房颤动（AF）患者发生出血事件的发生率，以及需要住院治疗的患者的管理成本。
2017 年 12 月至 2018 年 1 月期间，进行了一项全国性的电话调查，以确定治疗 AF 患者使用华法林的心脏病专家。共选择了 300 名心脏病专家，报告了过去 12 个月中接受 AF 华法林治疗的患者数量以及发生出血事件的患者数量。检索了 2013 年 1 月至 2017 年 6 月在雅典一家三级医院因华法林相关出血而住院的 AF 患者的医疗费用和资源利用成本。
在 48255 名 AF 患者中，有 12633 名（26.2%）接受了华法林治疗。所有患者中有 5.1%发生出血事件，其中出血需要住院治疗的发生率为 1.7%。最常见的出血部位是胃肠道系统（51.5%）。每例需要住院治疗的出血事件的平均（95%CI）管理费用为 1202 欧元（1058-1420 欧元）。颅内出血的费用更高，为 3887 欧元（2700-5046 欧元）。预计与华法林相关且需要住院治疗的出血事件的管理的年经济负担为 1463955 欧元。
希腊 AF 华法林治疗患者出血事件的发生率以及需要住院治疗的出血事件的估计年经济负担，强调需要遵循当前的指南并优化口服抗凝剂治疗 AF 副作用的治疗策略，尤其是在高出血风险的患者中。
